Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study | Zendy

Kevin J. Harrington | Zendy; Barbara Burtness | Zendy; Richard Greil | Zendy; Denis Soulières | Zendy; Makoto Tahara | Zendy; Gilberto de Castro | Zendy; Amanda Psyrri | Zendy; Irene Braña | Zendy; Neus Basté | Zendy; Prakash Neupane | Zendy; Åse Bratland | Zendy; Thorsten Fuereder | Zendy; Brett Hughes | Zendy; Ricard Mesı́a | Zendy; Nuttapong Ngamphaiboon | Zendy; Tamara Rordorf | Zendy; Wan Zamaniah Wan Ishak | Zendy; Jianxin Lin | Zendy; Burak Gümüşçü | Zendy; Ramona F. Swaby | Zendy; Danny Rischin | Zendy

Open Access

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Author(s) -

Kevin J. Harrington,

Barbara Burtness,

Richard Greil,

Denis Soulières,

Makoto Tahara,

Gilberto de Castro,

Amanda Psyrri,

Irene Braña,

Neus Basté,

Prakash Neupane,

Åse Bratland,

Thorsten Fuereder,

Brett Hughes,

Ricard Mesı́a,

Nuttapong Ngamphaiboon,

Tamara Rordorf,

Wan Zamaniah Wan Ishak,

Jianxin Lin,

Burak Gümüşçü,

Ramona F. Swaby,

Danny Rischin

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.21.02508

Subject(s) - pembrolizumab , medicine , hazard ratio , oncology , head and neck squamous cell carcinoma , chemotherapy , interquartile range , cetuximab , head and neck cancer , population , radiation therapy , cancer , immunotherapy , confidence interval , colorectal cancer , environmental health

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research